GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » DMK Pharmaceuticals Corp (OTCPK:DMKPQ) » Definitions » EPS without NRI

DMK Pharmaceuticals (DMK Pharmaceuticals) EPS without NRI : $-7.55 (TTM As of Sep. 2023)


View and export this data going back to 1995. Start your Free Trial

What is DMK Pharmaceuticals EPS without NRI?

DMK Pharmaceuticals's earnings per share without non-recurring items for the three months ended in Sep. 2023 was $-0.36. Its earnings per share without non-recurring items for the trailing twelve months (TTM) ended in Sep. 2023 was $-7.55.

During the past 3 years, the average earnings per share (NRI) Growth Rate was 31.50% per year. During the past 5 years, the average earnings per share (NRI) Growth Rate was 30.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using Earnings per share without Non-Recurring Items (NRI) data.

The historical rank and industry rank for DMK Pharmaceuticals's EPS without NRI or its related term are showing as below:

DMKPQ' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -375.9   Med: 9.3   Max: 81.1
Current: 31.5

During the past 13 years, DMK Pharmaceuticals's highest 3-Year average Earnings Per Share (NRI) Growth Rate was 81.10% per year. The lowest was -375.90% per year. And the median was 9.30% per year.

DMKPQ's 3-Year EPS without NRI Growth Rate is ranked better than
75.99% of 833 companies
in the Drug Manufacturers industry
Industry Median: 11.5 vs DMKPQ: 31.50

DMK Pharmaceuticals's EPS (Diluted) for the three months ended in Sep. 2023 was $-0.20. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-9.58.

DMK Pharmaceuticals's EPS (Basic) for the three months ended in Sep. 2023 was $-0.20. Its EPS (Basic) for the trailing twelve months (TTM) ended in Sep. 2023 was $-9.58.


DMK Pharmaceuticals EPS without NRI Historical Data

The historical data trend for DMK Pharmaceuticals's EPS without NRI can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DMK Pharmaceuticals EPS without NRI Chart

DMK Pharmaceuticals Annual Data
Trend Mar13 Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EPS without NRI
Get a 7-Day Free Trial Premium Member Only Premium Member Only -69.98 -37.81 -29.44 -15.90 -12.16

DMK Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EPS without NRI Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.02 -2.37 -3.07 -1.76 -0.36

Competitive Comparison of DMK Pharmaceuticals's EPS without NRI

For the Drug Manufacturers - Specialty & Generic subindustry, DMK Pharmaceuticals's PE Ratio without NRI, along with its competitors' market caps and PE Ratio without NRI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


DMK Pharmaceuticals's PE Ratio without NRI Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, DMK Pharmaceuticals's PE Ratio without NRI distribution charts can be found below:

* The bar in red indicates where DMK Pharmaceuticals's PE Ratio without NRI falls into.



DMK Pharmaceuticals EPS without NRI Calculation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock.

EPS without NRI for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


DMK Pharmaceuticals  (OTCPK:DMKPQ) EPS without NRI Explanation

EPS without NRI removes onetime and unusual items from EPS, to provide investors with a more accurate measure of the company’s true earnings. The earnings are adjusted for items that are irregular or unusual in nature, and/or are non-recurring. This is calculated using Net Income (Continuing Operations) plus/minus any tax affected unusual Items and Goodwill Impairments/Write Offs. This can be used to fairly measure a company's profitability.


Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.


DMK Pharmaceuticals EPS without NRI Related Terms

Thank you for viewing the detailed overview of DMK Pharmaceuticals's EPS without NRI provided by GuruFocus.com. Please click on the following links to see related term pages.


DMK Pharmaceuticals (DMK Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
Executives
Dorbin John W. Jr. officer: General Counsel C/O ARCIMOTO, INC., 2034 WEST 2ND AVENUE, EUGENE OR 97402
Seth Cohen officer: CFO C/O NEWTEK BUSINESS SERVICES,INC, 1440 BROADWAY, NEW YORK NY 10018
Ebrahim Versi director, officer: CEO 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Jannine Versi director 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Vickie S Reed director TORREYPINES THERAPEUTICS, INC., 11085 NORTH TORREY PINES RD, STE 300, LA JOLLA CA 92037
David J. Marguglio director 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Carlo Dennis J Phd director, 10 percent owner, officer: President/CEO PO BOX 1176, RANCHO SANTA FE CA 92067
Ronald B. Moss officer: Chief Medical Officer 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
David C. Benedicto officer: Chief Financial Officer 11682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Meera J. Desai director 1682 EL CAMINO REAL, STE 300, SAN DIEGO CA 92130
Robert O Hopkins officer: Chief Financial Officer 2658 DEL MAR HEIGHTS RD., #555, DEL MAR CA 92014
Karen K. Daniels officer: Vice President of Operations 11455 EL CAMINO REAL, SUITE 310, SAN DIEGO CA 92130
Howard C Birndorf director C/O NANOGEN INC, 10398 PACIFIC CENTER COURT, SAN DIEGO CA 92121
Roshawn A. Blunt director 11682 EL CAMINO REAL STE 300, SAN DIEGO CA 92130
Richard C Williams director 26001 OSPREY NEST COURT, BONITA SPRINGS FL 34134